NCT06588998 Xengenic Cortical Membranes Versus Connective Tissue Graft With Coronally Advanced Flap for the Treatment of Peri-implant Soft Tissue Dehiscences: A Randomized, Controlled Clinical Trial
| NCT ID | NCT06588998 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Amr Anwar Mohamed Ellithy Yousef |
| Condition | Immediate Implant |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2024-06-01 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Peri-implant soft tissue dehiscences represent a common complication in implant dentistry, often leading to esthetic and functional challenges. Current treatment options, including Xengenic cortical membranes and connective tissue graft with coronally advanced flap, aim to promote soft tissue regeneration and improve clinical outcomes. However, there is a need for comparative studies to determine the optimal treatment modality for peri-implant soft tissue dehiscences.
Eligibility Criteria
Inclusion Criteria: * Adults (20-50) years old. •peri-implant soft tissue dehiscence . •Thin gingival phenotype. •Optimal compliance as evidenced by no missing treatment appointments and positive attitude towards oral hygiene. Exclusion Criteria: * •Medically compromised patients and systemic conditions precluding implant and periodontal surgery. •Smokers, diabetics, pregnant or lactating women. •History of chemotherapy, radiotherapy in head and/or neck region. •Bisphosphonate therapy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06588998 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Immediate Implant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06588998 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06588998 currently recruiting?
Yes, NCT06588998 is actively recruiting participants. Contact the research team at amr.yousef@dent.tanta.edu.eg for enrollment information.
Where is the NCT06588998 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06588998 clinical trial?
NCT06588998 is sponsored by Amr Anwar Mohamed Ellithy Yousef. The trial plans to enroll 20 participants.